Swedish firm SyntheticMR has announced the acquisition of Finnish AI startup Combinostics for €4.3 million - less than the amount raised by the startup to date. Combinostics specializes in multimodal clinical decision support tools for brain health, integrating MRI analysis with clinical data such as CSF results to aid in diagnosing and managing neurological disorders like Alzheimer’s and multiple sclerosis.
SyntheticMR plans to leverage Combinostics’ AI-driven diagnostic tools alongside its own expertise in brain tissue characterization to create a unique offering for neurodegenerative disease management. This acquisition aligns with SyntheticMR’s strategy to expand its capabilities and accelerate product development, potentially enhancing its market position in neurology.
As this acquisition reflects a disappointing financial outcome for Combinostics' investors, it also underscores broader challenges facing the healthtech sector, with the startup's valuation indicative of a constrained funding environment. Despite this, SyntheticMR aims to capitalize on synergies to deliver improved clinical tools and grow its customer base starting in 2025.